Imaging Prostate Cancer With 18F-PSMA-1007 PET/CT Scans
Tests a PET scan tracer, 18F-PSMA-1007, to image prostate cancer in adults.
Plain-language title generated from the registry record
Registry title: The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
Key facts
- Where
- Wuxi, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT06723665, who can take part
Where in China
- Affiated Hospital of Jiangnan UniversityWuxi, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Affiliated Hospital of Jiangnan University
- Trial code
- NCT06723665
- Record updated
- 24 January 2025
- Original description
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.Read full original descriptionShow less
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.
Inclusion: Prostate cancer is clinically suspected. The patient was diagnosed with prostate cancer by biopsy. Prostate cancer needs to be evaluated after treatment.
Exclusion: Patients who did not meet the requirements as assessed by the investigator.